A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696

Trial Profile

A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Chronic heart failure
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Mar 2017 Planned End Date changed from 1 Aug 2018 to 30 Apr 2018.
    • 07 Mar 2017 Planned primary completion date changed from 1 Aug 2018 to 30 Apr 2018.
    • 26 Feb 2017 This trial is completed in Slovakia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top